get the price right and hvc market is ours

This great work done by California's Institute for Clinical and Economic Reform compares current HCV treatments with the new comers. While it is true that Gilead's sofosbuvir is significant improvement in the standard of care, the cost is astronomical, with no economic payback even after 20 years.

If BLT can get the price right for TT-034, we could wipe the floor with our competitors. At two thirds the cost of sofosbuvir, in California alone we could generate upwards of $10B pa.

Now what would that do to our share price? And then there is the rest of the world.

Massive upside for a company that has a MC below $100M.


"Using an estimate of the number of infected individuals in California who know of their
infection and would be considered for treatment, we estimate that replacing current care with
sofosbuvir-based regimens would raise drug expenditures by $18-$29 billion in a single year.
We looked for potential cost offsets to these initial costs of drug treatment that could result
from downstream reductions in liver-related complications following successful treatment of
hepatitis C infection. At a 5-year time horizon, however, cost offsets would be estimated to
represent less than 10-20% of upfront treatment costs. Even at a 20-year horizon, if all patients infected with hepatitis C are treated with new regimens, the cost offset will only cover
approximately two-thirds of initial drug costs."

http://ctaf.org/sites/default/files/assessments/CTAF_Hep_C_Draft_021214.pdf